TY - JOUR
T1 - Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia
T2 - An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials
AU - Kishi, Taro
AU - Matsui, Yuki
AU - Matsuda, Yuki
AU - Katsuki, Asuka
AU - Hori, Hikaru
AU - Yanagimoto, Hiroko
AU - Sanada, Kenji
AU - Morita, Kiichiro
AU - Yoshimura, Reiji
AU - Shoji, Yoshihisa
AU - Hagi, Katsuhiko
AU - Iwata, Nakao
N1 - Funding Information:
interest relevant to this study. No grant support or other sources of funding were used to conduct this study or prepare this article. Dr. Kishi has received speaker’s honoraria from Daiichi Sankyo, Sumitomo Dainippon, Eisai, Janssen, Otsuka, Meiji, MSD, and Tanabe-Mitsubishi (Yoshitomi) and has received a Health Labour Sciences Research Grant and a Fujita Health University School of Medicine research grant. Dr. Iwata has received speaker’s honoraria from Astellas, Sumitomo Dainippon, Eli Lilly, GlaxoSmithKline, Janssen, Yoshitomi, Otsuka, Meiji, Shionogi, Novartis and Pfizer. Dr. Matsui has nothing to disclose. Dr. Matsuda has received speaker’s honoraria from Sumitomo Dainippon, Eisai, Eli Lilly, GlaxoSmithKline, Otsuka, Tanae -Mitsu?ishi, and Pfizer and has a Grant-in-Aid for Young Scientists (B). Dr. Katsuki has received speaker’s honoraria from Sumitomo Dainippon and Meiji. Dr. Hori has received speaker’s honoraria from Sumitomo Dainippon, Eli Lilly, Janssen, Yoshitomi, Otsuka, Meiji, Shionogi, Novartis, and Pfizer. Dr. Yanagimoto has nothing to disclose. Dr. Kenji Sanada has received speaker’s honoraria from Sumitomo Dainippon, Meiji, Tanabe-Mitsubishi, and Eli Lilly. Dr. Morita has nothing to disclose. Professor. Yoshimura has received speaker’s honoraria from Eli Lilly, Janssen, Sumitomo Dainippon, Otsuka, Meiji, Pfizer, Shionogi, and
Funding Information:
We thank Dr. Kenji Sanada (Department of Psychiatry, Showa University School of Medicine, Tokyo, Japan), Dr. Kiichiro Morita (Cognitive and Molecular Research Institute of Brain Diseases, Kurume University, Kurume, Fukuoka, Japan), and Dr. Hikaru Hori (Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan) for providing unpublished data.
Publisher Copyright:
© Georg Thieme Verlag KG Stuttgart New York.
PY - 2019/3/7
Y1 - 2019/3/7
N2 - Introduction We conducted an updated systematic review and meta-analysis of randomized controlled trials (RCTs) comparing blonanserin with other antipsychotics (amisulpride, aripiprazole, haloperidol, paliperidone, and risperidone). Methods Weighted mean difference (WMD), risk ratio, and number needed to harm (NNH) with 95% confidence intervals (95% CIs) were calculated using random-effects model. Results Ten RCTs (n = 1521) were included in this study. Blonanserin was superior to aripiprazole in improvement of Positive and Negative Syndrome Scale total scores (WMD = -10.62, 95% CI = -17.67 to -3.560, p = 0.003). Blonanserin was associated with a higher incidence of all-cause discontinuation (RR = 1.373, 95% CI = 1.088-1.734, p = 0.008, NNH = 11), akathisia, extrapyramidal disorder, and agitation/excitement and a lower risk of hyperprolactinemia compared with risperidone + paliperidone. Discussion The current meta-analytic study did not update the comparison of blonanserin vs. haloperidol because there were no new RCTs. Our results suggest that the efficacy of blonanserin for schizophrenia is comparable with that of other antipsychotics, and blonanserin seems to be well tolerated.
AB - Introduction We conducted an updated systematic review and meta-analysis of randomized controlled trials (RCTs) comparing blonanserin with other antipsychotics (amisulpride, aripiprazole, haloperidol, paliperidone, and risperidone). Methods Weighted mean difference (WMD), risk ratio, and number needed to harm (NNH) with 95% confidence intervals (95% CIs) were calculated using random-effects model. Results Ten RCTs (n = 1521) were included in this study. Blonanserin was superior to aripiprazole in improvement of Positive and Negative Syndrome Scale total scores (WMD = -10.62, 95% CI = -17.67 to -3.560, p = 0.003). Blonanserin was associated with a higher incidence of all-cause discontinuation (RR = 1.373, 95% CI = 1.088-1.734, p = 0.008, NNH = 11), akathisia, extrapyramidal disorder, and agitation/excitement and a lower risk of hyperprolactinemia compared with risperidone + paliperidone. Discussion The current meta-analytic study did not update the comparison of blonanserin vs. haloperidol because there were no new RCTs. Our results suggest that the efficacy of blonanserin for schizophrenia is comparable with that of other antipsychotics, and blonanserin seems to be well tolerated.
UR - http://www.scopus.com/inward/record.url?scp=85043348163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043348163&partnerID=8YFLogxK
U2 - 10.1055/a-0574-0088
DO - 10.1055/a-0574-0088
M3 - Article
C2 - 29514360
AN - SCOPUS:85043348163
VL - 52
SP - 52
EP - 62
JO - Pharmakopsychiatrie und Neuropsychopharmakologie
JF - Pharmakopsychiatrie und Neuropsychopharmakologie
SN - 0176-3679
IS - 2
ER -